S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
OTCMKTS:SPHRY

Starpharma (SPHRY) Stock Forecast, Price & News

$5.58
-0.07 (-1.24%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.55
$5.67
50-Day Range
$5.30
$7.66
52-Week Range
$5.30
$13.73
Volume
4,486 shs
Average Volume
1,383 shs
Market Capitalization
$227.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.71
30 days | 90 days | 365 days | Advanced Chart
Receive SPHRY News and Ratings via Email

Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter.

Starpharma logo

About Starpharma

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SPHRY
CIK
N/A
Employees
50
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.61 million
Book Value
$1.15 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$227.35 million
Optionable
Not Optionable

Company Calendar

Today
5/18/2022
Fiscal Year End
6/30/2022

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Starpharma (OTCMKTS:SPHRY) Frequently Asked Questions

Who are Starpharma's key executives?
Starpharma's management team includes the following people:
  • Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director (Age 59, Pay $534.32k)
  • Mr. Nigel J. Baade B.Com, Grad. Dip., CPA, CFO & Company Sec.
What is Starpharma's stock symbol?

Starpharma trades on the OTCMKTS under the ticker symbol "SPHRY."

How do I buy shares of Starpharma?

Shares of SPHRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Starpharma's stock price today?

One share of SPHRY stock can currently be purchased for approximately $5.58.

How much money does Starpharma make?

Starpharma has a market capitalization of $227.35 million and generates $1.61 million in revenue each year.

How many employees does Starpharma have?

Starpharma employs 50 workers across the globe.

What is Starpharma's official website?

The official website for Starpharma is www.starpharma.com.

How can I contact Starpharma?

Starpharma's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company can be reached via phone at (138) 532-2700, via email at [email protected], or via fax at 61-3-9510-5955.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.